| Title           | Records Management and Retention         |
|-----------------|--|
| SOP #:          | OTO 104                                  |
| Version #:      | 3  |
| Effective Date: | July 22, 2020                            |
| Supersedes:     | OTO 104 Records Management and Retention |

## 1. POLICY

Investigators are responsible for maintaining study documents in accordance with applicable federal regulations, International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements and departmental procedures. Study documents must be readily accessible for audit by the Food and Drug Administration (FDA), approving Institutional Review Board (IRB), and/or departmental personnel as appointed by the Department Chair.

### 2. SCOPE

These policies and procedures apply to all personnel who conduct or are involved in research involving human subjects.

### 3. **RESPONSIBILITY**

The Principal Investigator is responsible for ensuring all study documentation is maintained in a complete, presentable and organized fashion. The Principal Investigator or designee must maintain and retain documents in adherence with this standard operating procedure.

### 4. APPLICABLE REGULATIONS AND GUIDELINES

| 21 CFR Part 11      | Electronic Records                                 |
|---------------------|--|
| 21 CFR Part 312.57  | Recordkeeping and record retention                 |
| 21 CFR Part 312.68  | Inspection of Investigator's Records and Reports   |
| 21 CFR Part 812.140 | Records  |
| 21 CFR Part 812.145 | Inspections  |
| ICH E6, 5.5         | Trial Management, Data Handling and Record Keeping |
|                     |  |

Health Insurance Portability and Accountability Act (HIPAA)

### 5. REFERENCES TO OTHER APPLICABLE SOPS

This SOP affects all other SOPs.

## 6. ATTACHMENTS

Attachment A: Protocol Training Log

Attachment B: Delegation of Authority Log

### 7. PROCESS OVERVIEW

- A. Location of research records Paper records
- B. Location of research records Electronic records
- C. Required regulatory documents
- D. Required subject documents
- E. Records retention

## 8. SPECIFIC PROCEDURES

## A. Location of research records – Paper records

| #  | Who                                      | Task  |
|----|--|---|
| 1. | Principal<br>Investigator or<br>designee | Ensure there is adequate space available for paper records required for the study.  |
|    | Principal<br>Investigator or<br>designee | Paper records must be stored in a locked cabinet with access limited to study personnel.  |
|    |  | Original records should be retained by the study team. The original informed consent must always be retained by the Principal Investigator or designee. |
|    | Note:                                    |   |

#### **B.** Location of research records – Electronic records

| #  | Who                        | Task   |  |
|----|----------------------------|--|--|
| 1. | All research personnel     | Electronic records must be stored in a manner to lessen the incidental or purposeful sharing of research information as much as possible. The following security features must be in place when storing electronic data: |  |
|    |                            | I. <b>Secure Storage.</b> Research data and records must <u>not</u> be stored<br>on an individual's hard drive unless it is encrypted and first<br>approved by the IRB <sup>1</sup> .                                    |  |
|    |                            | II. <b>Password protected.</b> Data must only be accessible by using a password unique to the individual (for databases) or the study (for Excel). Study approval documents do not need to be password protected.        |  |
|    |                            | III. <b>Limited access.</b> Access to electronic data and records must be limited to study personnel or a subset of study personnel.   |  |
| 2. |                            | Electronic research data associated with an Investigational Device Exemption (IDE) or an Investigational New Drug (IND) study must be compliant with 21 CFR Part 11.   |  |
|    | Note: <sup>1</sup> Excel s | preadsheets without password protection is not sufficient for data with PHI.   |  |

## C. Required regulatory documents

| #  | Who                                      | Task   |
|----|--|--|
| 1. | Principal<br>Investigator or<br>designee | Investigators must maintain up-to-date regulatory study documents based on the following matrix. Applicable documents must be readily available for inspection at all times. |
|    | Note:                                    |  |
|    |  |  |

| Document   | Format   | Requirement   |
|--|--|---|
|  | All Studies  |   |
| Protocol   | Paper or electronic  | All studies. All IRB-approved versions must be readily available.   |
| Protocol Training  | Paper or electronic. May use<br>Attachment A or email<br>confirmation of training. | All studies. Investigator must be<br>able to provide documentation<br>indicating protocol training for<br>study personnel. Study personnel<br>need to be retrained to the<br>protocol when it is revised. |
| Informed Consent   | Paper or electronic  | All studies involving informed consent. All IRB-approved versions must be readily available.  |
| Delegation of Authority                                  | Paper or electronic. Use<br>Attachment B   | All studies requiring expedited or full board review.   |
| Curriculum Vitae (CV)                                    | Paper or electronic  | A copy of each study personnel's<br>CV to indicate qualification by<br>training and experience.   |
| Hospital / RI Approvals                                  | Paper or electronic  | All studies requiring IRB approval.   |
| IRB Approvals  | Paper or electronic  | All studies requiring IRB approval.<br>Must maintain record of all<br>submissions, approvals,<br>stipulations, and responses.   |
| IRB Correspondence                                       | Paper or electronic  | All studies requiring IRB approval.   |
| Adverse Events   | Paper or electronic  | All reports of adverse events.<br>Copies of reports to IRB and<br>sponsor where applicable.   |
| Recruitment materials                                    | Paper or electronic  | All approved by IRB.  |
| <b>•</b>   | xemption (IDE) or Inves<br>le above requirements p                                 | tigational New Drug (IND)<br>Ilus the following:  |
| FDA Form 1572 (IND) or<br>Investigator's Agreement (IDE) | Paper  | All versions signed and dated   |
| Financial Disclosures                                    | Paper or electronic  | All versions signed and dated   |
| Investigator's Brochure                                  | Paper or electronic  | All versions approved by IRB  |
| Professional licenses,<br>certificates                   | Paper  | Applicable documentation<br>covering entire time span<br>individual is active on study  |
| Sponsor Correspondence                                   | Paper or electronic  | Must keep all correspondence<br>associated with study. This<br>includes emails, phone logs, site<br>letters, mail, etc.   |
| Equipment certifications                                 | Paper or electronic  | Must maintain copies of equipment certificates if used in study (i.e., calibration certificates).   |

| Document  | Format              | Requirement  |
|---|---------------------|--|
| Subject Enrollment Log  | Paper or electronic | Log indicating all subjects who<br>signed consent, including screen<br>failures and withdrawals.   |
| Site Visit Log  | Paper or electronic | Log indicating when the trial was monitored and by whom.   |
| Protocol Waiver/Deviation Log                                   | Paper or electronic | Log listing any and all protocol<br>waivers and deviations. Include<br>supporting documentation where<br>applicable.   |
| Training records  | Paper or electronic | Documentation of training<br>completed by study staff. This<br>includes general research training<br>and study specific training.  |
| Drug and/or device<br>accountability logs                       | Paper               | Record of receiving, dispersing<br>and returning investigational<br>product for each subject. Includes<br>log and shipping receipts as<br>applicable. May reside with<br>pharmacy. |
| Case Report Forms – blank set                                   | Paper or electronic | Copy of readily available case report forms.   |
| Data Safety Monitoring Board<br>(DSMB) reports, when applicable | Paper or electronic | Maintain copies of reports for studies that have a DSMB.   |
| Audit documentation, when applicable                            | Paper or electronic | Keep copies of documents related<br>to internal and external study<br>audits. This includes corrective<br>action plans and any<br>correspondence surrounding the<br>audit.         |

# D. Required subject documents

| #  | Who                                      | Task  |
|----|--|---|
| 2. | Principal<br>Investigator or<br>designee | Investigators must maintain up-to-date subject documentation based on the following matrix. Applicable documents must be readily available for inspection at all times. |
|    | Note:                                    |   |

| Document                                 | Format                                     | Requirement  |
|--|--|--|
|  | All Studies                                |  |
| Signed Informed Consent, when applicable | Paper – original                           | All signed informed consent documents must be retained. This |
| applicable                               | OR   | includes screen failures and                                 |
|  | Electronic – original (if approved by IRB) | withdrawals.   |

| Document                            | Format   | Requirement  |
|-------------------------------------|--|--|
| Signed HIPAA forms, when applicable | Paper – original or<br>Electronic - original     | All signed HIPAA authorizations<br>must be retained. This includes<br>screen failures and withdrawals.                       |
| Candidacy Checklist                 | Paper or electronic (if never recorded on paper) | Documentation that the subject meets candidacy criteria.   |
| Case Report Forms - completed       | Paper or electronic (if never recorded on paper) | All completed forms for each subject.  |
| Source documentation                | Paper or electronic                              | Original documentation of<br>participant test results, medical<br>history, and/or questionnaires as<br>required by protocol. |

### E. Records Retention

.

Study records must be retained for a specific amount of time depending on the regulations and policies that apply to the specific research study. For studies where multiple regulations and/or policies apply, the records must be maintained for the period which is longest.

| Regulated by: | Retention Period   |
|---------------|--|
| HIPAA         | 7 years after closure with IRB   |
| NIH           | > 3 years from the date the Final Financial Status<br>Report is submitted  |
| FDA – IND     | 2 years following the date a marketing application<br>is approved or abandoned (or as required by<br>sponsor)        |
| FDA – IDE     | 2 years following the date a product receives pre-<br>market approval or is abandoned (or as required<br>by sponsor) |
| VA            | Indefinitely (until otherwise approved by VA)  |
| СНСО          | Youngest child in the study turns 28 years old   |